Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2021-09-09 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시)(전환우선주 전환가액 조정)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Gencurix regarding the adjustment of the conversion price of convertible preferred shares due to a decline in market price. This type of disclosure, which involves changes to the capital structure and conversion terms of securities, falls under the category of 'Share Issue/Capital Change' (SHA) as it directly impacts the company's equity and potential share dilution.
2021-09-09 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Gencurix regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This falls under capital structure changes and financing updates, specifically related to convertible debt instruments.
2021-09-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (directors/executives). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels and related party holdings.
2021-09-08 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Gencurix Inc. for the period 2021.01.01 to 2021.06.30. It contains detailed financial information, business descriptions, capital structure, and management details, which are characteristic of an interim/quarterly report. It is not a mere announcement or certification, as it provides substantive financial data and operational details. H1 2021
2021-08-27 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고' (Correction Report). It details changes to stock option grants, including the number of shares and the list of recipients. This type of disclosure regarding capital structure and equity-based compensation for employees/directors falls under the category of Regulatory Filings (RNS) as it is a specific corporate announcement filed with the financial authorities.
2021-08-17 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients. This type of filing is a standard regulatory disclosure regarding capital structure and equity compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration Information' (which is typically for executive compensation disclosures in proxy statements).
2021-08-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.